VANCOUVER, BC / ACCESSWIRE / July 19, 2016 / Canadian Zeolite Corp. (the “Company”) (TSX.V: CNZ) reports that further to its July 6, 2016 news release that processing of the Company’s Bromley Creek zeolite is now underway at the Kamloops processing facility. This initial mill run will provide specific sized zeolite for green-tech applications.

Contact with a long list of customer enquiries from the past several months is on-going. “Having processed zeolite is another huge step forward in being able to provide customers with our zeolite for their end use in areas such as odour reduction for municipal composting, agricultural growing mediums, animal feed supplements, road salt replacement, waste-water filtration, artificial turf odour and moisture control and radio-active waste containment. We will continue to move the Company forward with our singular focus in establishing Canadian Zeolite Corp. as the #1 zeolite supplier in Canada, by increasing awareness for using natural zeolite for green-tech solutions,” stated Ray Paquette CEO.

The Company plans to pursue municipal composting opportunities across Canada. Cities and municipalities across Canada are now separating all compostable materials from trash collection. The Compost Council of Canada states: “organics residuals are the largest component of the waste stream.” Diverting organic waste from the municipal waste system benefits the sustainability of the community by extending the life of landfills and reducing the potential for leachate and the production of methane. One of the most significant issues facing composting facilities is the control of odour emissions. If you live near or have driven by a composting facility, you’ll appreciate the challenge municipalities have with controlling the odour emitted from composting. Canadian Zeolite contributed its natural micronized zeolite for a large scale composting study with the Region of Peel in Ontario to address these odour emission issues. The results were a remarkable reduction of 81-85% of odour emissions.

Canadian Zeolite’s 30.8 hectare Mining Lease #380929 lies within the 1145 hectare Bromley Creek Property. The Company’s Quarry Permit Q-15-012 allows the annual extraction of 50,000 tonnes of zeolite and the quarry can be increased as required.

R. Tim Henneberry P.GEO Canadian Zeolite’s Qualified Person has reviewed and approved the scientific and technical information contained in this press release.

The Company is not basing its production decision on a feasibility study of mineral reserves demonstrating the economic and technical viability. As a result there is increased uncertainty and economic and technical risk of failure associated with the production decision.

On behalf of the Board of Directors
“Ray Paquette”
President & CEO
604.684.3301
www.canadianzeolite.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Some statements in this news release contain forward-looking information. These statements include, but are not limited to, statements with respect to future expenditures. These statements address future events and conditions and, as such, involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the statements. Such factors include, among others, the ability to complete contemplated work programs and the timing and amount of expenditures. Canadian Zeolite does not assume the obligation to update any forward-looking statement.

SOURCE: Canadian Zeolite Corp.

ReleaseID: 442549

IRVINE, CA / ACCESSWIRE / July 19, 2016 / Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against Gerdau S.A. (“Gerdau” or the “Company”) (NYSE: GGB). Investors who purchased or otherwise acquired shares between June 2, 2011 and May 15, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the July 25, 2016 lead plaintiff motion deadline.

If you purchased shares of Gerdau during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the complaint, Gerdau issued false and misleading statements to investors and/or failed to disclose that: the Company was engaged in a bribery scheme with Brazil’s Board of Tax Appeals; Gerdau defrauded Brazilian tax authorities of about $429 million; the Company’s Chief Executive Officer and other directors and employees engaged in bribery, money laundering, and peddling for influence; and as a result of the above, Gerdau’s public statements were materially false and misleading throughout the Class Period.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 442584

LOS ANGELES, CA / ACCESSWIRE / July 19, 2016 / Lundin Law PC announces a class action lawsuit has been filed against Tangoe, Inc. (“Tangoe” or the “Company”) (NASDAQ: TNGO) concerning possible violations of federal securities laws between March 18, 2014 and March 7, 2016 (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the July 25, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, during the Class Period, Tangoe issued false and misleading information and or/failed to disclose that: the Company made errors in recognizing its revenue; Tangoe’s financial results were overstated; and as a result of the above, statements about the Company’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 442583

Developing Potent Antibiotics to Treat Serious Multi-Drug Resistant Infections

Report Available here: www.lifescicapital.com/equity-research/achaogen/

NEW YORK, NY / ACCESSWIRE / July 19, 2016 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of Achaogen (NasdaqGM: AKAO), a biotechnology company developing novel antibiotics to combat the rise of bacterial resistance. Achaogen’s lead product candidate is plazomicin, a potent antibiotic with activity against a broad range of serious gram negative, multi-drug resistant (MDR) pathogens.

Plazomicin has been designed with two key chemical modifications to overcome most known mechanisms of resistance to aminoglycosides. The Centers for Disease Control and Prevention (CDC) consider resistance to this antibiotic class, an important last-line of defense against multidrug-resistant (MDR) pathogens, to be one of the most pressing public health threats. Carbapenem-resistant Enterobacteriaceae (CRE) are resistant to most commercially available drugs and are associated with particularly high mortality rates. Achaogen expects to report data from two Phase III trials in the first half of 2017, which could position the Company to file an NDA for plazomicin in the second half of 2017.

In a 35 page Initiation Report, LifeSci Capital explains the Company’s development strategy, the landscape of existing therapies, and the favorable shift in regulatory and economic environment that now support development in the antibiotic space.

Dr. Isaacson’s full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on Achaogen as developments occur.

The LifeSci Capital research team is led by Dr. Jerry Isaacson, an industry veteran with broad experience in biotechnology, having worked in both public and private biotech companies in areas ranging from medicinal chemistry and analytical chemistry to patents and investor/public relations. Dr. Isaacson holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego.

About LifeSci Capital:

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients’ businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company’s website, www.lifescicapital.com.

Analyst Contact:

Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: jisaacson@lifescicapital.com

SOURCE: LifeSci Capital, LLC

ReleaseID: 442585

IRVINE, CA / ACCESSWIRE / July 19, 2016 / Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against Endo International plc (“Endo” or the “Company”) (NASDAQ: ENDP). Investors who purchased or otherwise acquired shares between March 2, 2015 and May 6, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the July 25, 2016 lead plaintiff motion deadline.

If you purchased shares of Endo during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by email at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The complaint alleges that the Company failed to disclose: that Endo’s arrangements with pharmacy benefit managers with respect to the migraine therapy, Frova, included questionable incentives intended to increase sales revenues; and as a result, Endo’s revenues and revenue projections relied in part on unsustainable arrangements.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by email at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts:

KHANG & KHANG LLP
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang Khang LLP

ReleaseID: 442582

LAS VEGAS, NV / ACCESWIRE / July 19, 2016 / South American Gold Corp. (PINKSHEETS: SAGD) announced this week that they are eyeing international interest in the emerging cannabis market as an opportunity to accelerate their revenue development plans and product distribution strategy. Citing statements made by Jim Hagedorn, the CEO of Scotts Miracle-Gro to a Forbes news reporter, South American Gold Corp. feels very well positioned to take advantage of a frantic market rush into the legalized cannabis space. Mr. Hagedorn recently spoke with Forbes reporter Dan Alexander about his vision for capitalizing on cannabis, “It is the biggest thing I’ve ever seen in lawn and garden,” Hagedorn has gone far beyond just talking about the opportunities, and has invested heavily in this emerging market. He invested $135 million last year on two California-based businesses that sell fertilizers, soils and accessories to pot growers and, more recently, spent another $120 million on a still-undisclosed lighting and hydroponics equipment company in Amsterdam. He has also stated that he plans to invest approximately $150 million more by the end of 2016. These investments combined, make this investment larger than any acquisition in the history of Scotts Miracle-Gro. 

“It is obvious that more and more businesses are taking the Cannabis market seriously,” stated South American Gold Corp.’s CEO Cynthia Berain, “as more and more governments move to legalize cannabis use and products I think you will find more and more companies running into this space. These recent comments from Scotts Miracle-Gro are just a good example of that happening.”

Ms. Berain continued, “What is most exciting for us is that we are on the forefront of this movement and we are very well positioned to profit greatly from this broad market trend because we have the products, leadership and we are developing the infrastructure necessary to be a major market participant in this sector.”

About SAGD: South American Gold Corp is focused on becoming the premiere provider of value added products and services for the cultivation and processing of cannabis for the South American medical and recreational markets with an initial focus on the Uruguayan market.

Disclaimer

This release contains forward-looking statements that are based on beliefs of South American Gold Corp. management and reflect South American Gold Corp.’s current expectations as contemplated under section 27A of the Securities Act of 1933, as amended, and section 21E of the Securities and Exchange Act of 1934, as amended. When we use in this release the words “estimate,” “project,” “believe,” “anticipate,” “intend,” “expect,” “plan,” “predict,” “may,” “should,” “will,” “can,” the negative of these words, or such other variations thereon, or comparable terminology, are all intended to identify forward looking statements. Such statements reflect the current views of South America Gold Corp. with respect to future events based on currently available information and are subject to numerous assumptions, risks and uncertainties, including but not limited to, risks and uncertainties pertaining to development of mining properties, changes in economic conditions and other risks, uncertainties and factors, which may cause the actual results, performance, or achievement expressed or implied by such forward looking statements to differ materially from the forward looking statements. The information contained in this press release is historical in nature, has not been updated, and is current only to the date shown in this press release. This information may no longer be accurate and therefore you should not rely on the information contained in this press release. To the extent permitted by law, South American Gold Corp. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission. This press release incorporates by reference the Company’s filings with the SEC including 10K, 10Q, 8K reports and other filings. Investors are encouraged to review all filings. There is no assurance South American Gold Corp. will identify projects of merit or if it will have sufficient financing to implement its business plan. There is no assurance that the Company’s due diligence on the potential acquisition of oil and gas assets will be favorable nor that definitive terms can be negotiated. Information in this release includes representations from the private companies referred to which has not been independently verified by the company. A downturn in oil prices would affect the potential profitability of the proposed acquisition negatively.

SOURCE: South American Gold Corp.

ReleaseID: 442586

IRVINE, CA / ACCESSWIRE / July 19, 2016 / Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against Unilife Corporation (“Unilife” or the “Company”) (NASDAQ: UNIS). Investors who purchased or otherwise acquired shares between February 3, 2014 and May 23, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the July 25, 2016 lead plaintiff motion deadline.

If you purchased shares of Unilife during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the complaint, Unilife made false and misleading statements and/or failed to disclose that: the Company’s former Chief Executive Officer and former Chairman of the Board of Directors had violated the Company’s policies and procedures and had engaged in violations of law and regulation; the Company lacked adequate internal controls over accounting and financial reporting; as a result of the above Unilife could not file its Quarterly Report on Form 10-Q by the filing deadline. Upon release of this news, the Company’s stock price fell.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 442580